These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 3441327)

  • 1. Strontium kinetics in metastasized prostatic carcinoma: a comparison with the predictions of impulse response function analysis.
    Blake GM; Zivanovic MA; Gray JM
    Nucl Med Commun; 1987 Nov; 8(11):909-19. PubMed ID: 3441327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 89Sr therapy: strontium plasma clearance in disseminated prostatic carcinoma.
    Blake GM; Wood JF; Wood PJ; Zivanovic MA; Lewington VJ
    Eur J Nucl Med; 1989; 15(1):49-54. PubMed ID: 2537216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strontium-89 radionuclide therapy: a dosimetric study using impulse response function analysis.
    Blake GM; Gray JM; Zivanovic MA; McEwan AJ; Fleming JS; Ackery DM
    Br J Radiol; 1987 Jul; 60(715):685-92. PubMed ID: 3620827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma.
    Breen SL; Powe JE; Porter AT
    J Nucl Med; 1992 Jul; 33(7):1316-23. PubMed ID: 1613572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurements of the strontium plasma clearance rate in patients receiving 89Sr radionuclide therapy.
    Blake GM; Zivanovic MA; Lewington VJ
    Eur J Nucl Med; 1989; 15(12):780-3. PubMed ID: 2516486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate.
    Blake GM; Zivanovic MA; McEwan AJ; Ackery DM
    Eur J Nucl Med; 1986; 12(9):447-54. PubMed ID: 3102236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 89Sr radionuclide therapy: dosimetry and haematological toxicity in two patients with metastasising prostatic carcinoma.
    Blake GM; Zivanovic MA; McEwan AJ; Batty VB; Ackery DM
    Eur J Nucl Med; 1987; 13(1):41-6. PubMed ID: 3109917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases.
    Blake GM; Zivanovic MA; Blaquiere RM; Fine DR; McEwan AJ; Ackery DM
    J Nucl Med; 1988 Apr; 29(4):549-57. PubMed ID: 3351609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palliation of multiple bone metastases from prostatic carcinoma with strontium-89.
    Tennvall J; Darte L; Lundgren R; el Hassan AM
    Acta Oncol; 1988; 27(4):365-9. PubMed ID: 2462438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of human biokinetics of strontium on internal ingestion dose of 90Sr and absorbed dose of 89Sr to organs and metastases.
    Li WB; Höllriegl V; Roth P; Oeh U
    Radiat Environ Biophys; 2008 Apr; 47(2):225-39. PubMed ID: 18204850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strontium 89 therapy for the palliation of pain due to osseous metastases.
    Robinson RG; Preston DF; Schiefelbein M; Baxter KG
    JAMA; 1995 Aug; 274(5):420-4. PubMed ID: 7542352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD; Crook JM; Lukka H
    Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective accumulation of strontium-89 in metastatic deposits in bone: radio-histological correlation.
    Ben-Josef E; Lucas DR; Vasan S; Porter AT
    Nucl Med Commun; 1995 Jun; 16(6):457-63. PubMed ID: 7545802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of metastatic bone pain with strontium-89.
    Robinson RG; Spicer JA; Preston DF; Wegst AV; Martin NL
    Int J Rad Appl Instrum B; 1987; 14(3):219-22. PubMed ID: 3667305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strontium-89 therapy: strontium kinetics and dosimetry in two patients treated for metastasising osteosarcoma.
    Blake GM; Zivanovic MA; McEwan AJ; Condon BR; Ackery DM
    Br J Radiol; 1987 Mar; 60(711):253-9. PubMed ID: 3471288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma.
    Buchali K; Correns HJ; Schuerer M; Schnorr D; Lips H; Sydow K
    Eur J Nucl Med; 1988; 14(7-8):349-51. PubMed ID: 2460352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematologic depression following therapy with strontium-89 chloride.
    Cowan RJ; Chilton HM; Cooper MR; Ferree CR; Watson EE; Robinson RG
    Clin Nucl Med; 1986 Dec; 11(12):845-6. PubMed ID: 2434277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strontium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship?
    Mertens WC; Stitt L; Porter AT
    Am J Clin Oncol; 1993 Jun; 16(3):238-42. PubMed ID: 7687818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89?
    Dearnaley DP; Bayly RJ; A'Hern RP; Gadd J; Zivanovic MM; Lewington VJ
    Clin Oncol (R Coll Radiol); 1992 Mar; 4(2):101-7. PubMed ID: 1372817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate.
    Paszkowski AL; Hewitt DJ; Taylor A
    Clin Nucl Med; 1999 Nov; 24(11):852-4. PubMed ID: 10551466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.